Sarcoma / 2013 / Article

Erratum | Open Access

Volume 2013 |Article ID 757915 | 2 pages |

Erratum to “Desmoid Fibromatosis in Pediatric Patients: Management Based on a Retrospective Analysis of 59 Patients and a Review of the Literature”

Received16 Jan 2013
Accepted31 Jan 2013
Published06 Mar 2013

We need to update the first and third addresses as shown above. Furthermore, “zero” has been modified and replaced by “—” in Table 3.

CRPROverall response (%)SDPDUnknown response (%)

VA611 (17%)5
IVA13314 (30%) 9
VAC and tamoxifen11
Vinblastine-MTX1477 (50%)511
Vinblastine-MTX-tamoxifen733 (43%)31
Doxorubicin with other agents*522 (40%)3
Imatinib mesylate22
Others+1022 (20%)17

Total6131619 (31%)27 (44%)12 (20%)3 (5%)

VA: vincristine and dactinomycin; IVA: ifosfamide, vincristine and dactinomycin; VAC: vincristine, dactinomycin, and cyclophosphamide; MTX: methotrexate. : number of patients; CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease.
*Doxorubicin with vincristine, cisplatin, ifosfamide, cyclophosphamide, or tamoxifen.
+Others: VINCAEPI (vincristine, carboplatin, and VM 26), MMT95 protocol (IVA, etoposide, epirubicin, and carboplatin), dactinomycin alone, etoposide-ifosfamide, etoposide alone, and carboplatin.

Copyright © 2013 Caroline Oudot et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

806 Views | 489 Downloads | 3 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19.